A site where you can find recommended contractors for non-clinical testing｜effical " Non-Clinical CROs and Agencies " Cellomatics BioSciences Ltd.

Cellomatics BioSciences Ltd.

Cellomatics BioSciences Ltd. is a Nottingham-based preclinical-stage contract research organization (CRO) that provides support for drug development. In this article, we investigate and summarize the features of the company's contract non-clinical study services, the disease models it offers, and examples of non-clinical studies.

Cellomatics BioSciences Ltd.' Contract Nonclinical Trial Services Feature

Custom assay development to meet client needs

Cellomatics BioSciences Ltd,Develop assays (test methods) to help evaluate the efficacy of test compounds and provide customized servicesWe do this service. This service considers a variety of factors, including relevance, reproducibility, quality, interference, and cost,Customization to meet client needs and support from planning to completionI will do so.

We develop a variety of in vitro assays, primarily for biopharmaceutical and biotechnology companies. We provide the screening and evaluation needed at each stage of a drug development program.

A wide variety of facilities

To meet the diverse experimental needs of its clients, Cellomatics BioSciences Ltd. has installed a variety of equipment. The company has a powerful high-resolution imaging platform, theImageXpress® Pico Automated Cell Imaging Systemand high performance flow cytometer with user-friendly operation screen2020 Attune NxT Flow CytometerWe have also introduced a new system for the production of cellular biology. Through these investments, we are strengthening our technical capabilities to meet the needs of molecular cell biology.

Develop in vitro models with high predictive validity

Advanced in vitro experimental platform designed to reproduce human physiology, disease pathophysiology, and pharmacological responsesDevelopment of Translational Human Preclinical ModelsWe are currently working on a new series of models. These models encompass primary human cells, induced pluripotent stem cell-derived models, organoids, and 3D co-culture systems, and can provide higher predictive validity than traditional models.

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

Example of a pathological model owned by Cellomatics BioSciences Ltd.

INNOBEX, developed by Cellomatics BioSciences Ltd., is,Models designed to reproduce the complex structure and function of the human blood-brain barrier (BBB)It is. Using this model, drug compounds and their interactions within the BBB can be analyzed in detail. The company also uses primary human keratinocytes (keratinocytes) and freshly isolated immune cells,Also offers a model that faithfully reproduces the characteristics of psoriasisThe company is doing so.

Cellomatics BioSciences Ltd. Non-clinical Case Studies

No specific case studies were available on the official website.

Cellomatics BioSciences Ltd. Company Information

Cellomatics BioSciences Ltd. was founded in 2015. It provides preclinical in vitro bioassay services, specializing in therapeutic areas such as oncology, immuno-oncology, immunology and inflammation. The company evaluates the efficacy and safety of drugs to support research and development decisions.

Address	10 Colwick Quays Business Park Road No2, Colwick v Nottingham, Nottinghamshire, NG4 2JY, GB
Tel	+44 (0)115 865 4101
Website	https://cellomaticsbio.com/

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us